# Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1

> **NCT00657202** · EARLY_PHASE1 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 11 (actual)

## Conditions studied

- Neurofibromatosis Type 1
- Cutaneous Neurofibromas

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT00657202
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2009-10
- **Final completion:** 2013-12
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2016-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00657202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00657202, "Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00657202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*